What does Dynavax Technologies Corp. do?

Jun 22 2025 06:25 PM IST
share
Share Via
Dynavax Technologies Corp. is a clinical-stage immunotherapy company that focuses on stimulating immune responses through toll-like receptor activation. As of March 2025, it reported net sales of $68 million and a net loss of $96 million, with a market cap of approximately $1.2 billion.
Overview:
Dynavax Technologies Corporation is a clinical-stage immunotherapy company focused on leveraging the body's immune responses through toll-like receptor stimulation, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.

Financial Snapshot:
Most recent Net Sales: 68 Million (Quarterly Results - Mar 2025)
Most recent Net Profit: -96 Million (Quarterly Results - Mar 2025)
Market-cap: USD 1,199.61 Million (Micro Cap)

Key Metrics:
P/E: 54.00
Dividend Yield: 0.00%
Debt Equity: -0.75
Return on Equity: 4.27%
Price to Book: 2.26

Contact Details:
Address: 2100 POWELL STREET, SUITE 900, EMERYVILLE CA: 94608
Tel: 1 510 8485100
Fax: 1 510 8481327
Website: http://www.dynavax.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News